Biogen (BIIB) October IV elevated into topline
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) September option implied volatility is at 55, October is at 78; compared to its 52-week range 29 to 73 into topline phase 3 data for Alzheimer's drug lecanemab.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $280 at Guggenheim
- IBM (IBM) call put ratio 2.3 calls to 1 put into quarter results
- AT&T (T) call put ratio 2.4 calls to 1 put into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
